Please note that trial status changes frequently, so please return to this page often for updates. HIV negative Patients are randomized to either take one of three doses of Entecavir or continue Lamivudine. At treatment week 24, response is assessed and those that are responding will continue study medication for another 24 weeks. Non-responders will be taken out of the study and receive open level Entecavir plus Lamivudine. Liver biopsies are optional.
Study pays for drugs, labs, biopsies, and doctors visits while in the study.
Adefovir is supplied by manufacturer. Labs are billed to the patient's insurance. Liver biopsy is requested if safe to perform. NIH is sponsoring a clinical trial in hepatitis C patients who failed to respond to previous treatments to determine the effectiveness of long-term antiviral therapy in the prevention of cirrhosis, liver failure, and cancer. The University of Michigan Hepatitis program has been selected as one of 9 centers nationwide to participate in this important trial.